E. Brian Butler, MD

Jim and Joan Harrell Chair in Radiation Oncology, Department of Radiation Oncology
Professor of Radiation Oncology, Institute for Academic Medicine
Full Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


After completing his postdoctoral training in 1987, Dr. Butler returned to the Wilford Hall USAF Medical Center in San Antonio, Texas where he became both the Chief of Radiation Oncology and the Chief of Brachytherapy. He also joined the faculty at The University of Texas Health Science Center at San Antonio as a Clinical Assistant Professor that same year. Dr. Butler would later join the Baylor College of Medicine where he would eventually become a full professor and the Chief of Radiation Oncology for both the medical school and the VA Hospital. He became the Medical Director of Radiation Oncology at Methodist in 1991, and received his faculty appointment at the Weill Medical School in 2006.

Description of Research

Dr. Butler’s research centers on preclinical and clinical studies that combine radiation therapy and gene therapy for the treatment of prostate cancer. In recent years, he has extended these successful studies to other cancers, notably pancreatic cancer. His research interests also include three-dimensional reconstruction of body organs to assist in better localization of radiation therapy.

Areas Of Expertise

Radiation therapy Prostate cancer Gene therapy Pancreatic cancer Computer visualization techniques
Education & Training

Residency, Stanford School of Medicine
MD, Georgetown University


Patent Number: US2018125780, May 10 2018


Patent Number: WO2016187100, Nov 24 2016


Postmastectomy radiation therapy for triple negative, node-negative breast cancer
Haque, WM, Verma, V, Farach, AM, Butler, EB & Teh, BS 2019, Radiotherapy and Oncology, vol. 132, pp. 48-54. https://doi.org/10.1016/j.radonc.2018.11.012

Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma
Haque, WM, Arms, A, Verma, V, Hatch, S, Brian Butler, E & Teh, BS 2019, Breast, vol. 43, pp. 67-73. https://doi.org/10.1016/j.breast.2018.11.007

Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer
Haque, WM, Verma, V, Butler, EB, Teh, BS & Rusthoven, CG 2019, Lung Cancer, vol. 127, pp. 76-83. https://doi.org/10.1016/j.lungcan.2018.11.026

Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century
Dalwadi, SM, Lewis, GD, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2019, Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2018.11.004

Stereotactic radiosurgery for brain metastases from newly diagnosed small cell lung cancer: practice patterns and outcomes
Jiang, W, Haque, WM, Verma, V, Butler, EB & Teh, BS 2019, Acta Oncologica. https://doi.org/10.1080/0284186X.2018.1562207

Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma
Ryckman, JM, Surkar, SM, Haque, WM, Butler, EB, Teh, BS & Verma, V 2019, American Journal of Clinical Oncology: Cancer Clinical Trials. https://doi.org/10.1097/COC.0000000000000511

Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy for cancer treatment
Chua, CYX, Filgueira, CS & Grattoni, A 2018, SITC 33rd Annual Meeting, Washington DC, United States, 11/9/18 - 11/11/18, .

Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes
Haque, WM, Verma, V, Hatch, S, Klimberg, VS, Butler, EB & Teh, BS 2018, Breast, vol. 41, pp. 67-73. https://doi.org/10.1016/j.breast.2018.06.014

Intratumoral Immunotherapy Delivery Via Minimally Invasive Nanochannel Implant
Susnjar, A, Chua, CYX, Rhudy, JR, Ho, J, Jain, P, Singh, S, Yee, C, Filgueira, CS, Butler, EB & Grattoni, A 2018, 2018 AIChE Annual Meeting, 3rd Bioengineering & Translational Medicine Conference, Boston, United States, 9/27/18 - 9/28/18, .

Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer
Chua, CYX, Jain, P, Susnjar, A, Rhudy, J, Folci, M, Ballerini, A, Gilbert, A, Singh, S, Bruno, G, Filgueira, CS, Yee, C, Butler, EB & Grattoni, A 2018, Journal of Controlled Release, vol. 285, pp. 23-34. https://doi.org/10.1016/j.jconrel.2018.06.035

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma
Qin, Q, Nan, X, Miller, TN, Fisher, R, Teh, BS, Pandita, S, Farach, AM, Pingali, SR, Pandita, RK, Butler, EB, Pandita, TK & Iyer, SP 2018, Radiation Research, vol. 190, no. 3, pp. 322-329. https://doi.org/10.1667/RR15048.1

Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion
Cushman, TR, Haque, WM, Menon, H, Rusthoven, CG, Butler, EB, Teh, BS & Verma, V 2018, Journal of gynecologic oncology, vol. 29, no. 6, e97, pp. e97. https://doi.org/10.3802/jgo.2018.29.e97

Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 4, pp. 601-609. https://doi.org/10.21037/jgo.2018.05.08

Nanofluidic Drug-eluting Seed For Sustained Intratumoral Immunotherapy Delivery In Breast Cancer
Chua, CYX, Jain, P, Folci, M, Ballerini, A, Rhudy, JR, Singh, S, Bruno, G, Susnjar, A, Filgueira, CS, Yee, C, Butler, EB & Grattoni, A 2018, Annual Meeting & Exposition of the Controlled Release Society, 7/22/18 - 7/24/18, .

Utilization of intensity modulated radiation therapy for anal cancer in the United States
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 3, pp. 466-477. https://doi.org/10.21037/jgo.2018.03.03

Grattoni, A, Butler, EB & Palapattu, G 2018, , Patent No. US2018125780, IPC No. A61M 37/ 00 A I.

Utilization of hysterectomy following chemoradiation for IB2/IIA2 cervical cancer in the national cancer data base
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Anticancer Research, vol. 38, no. 5, pp. 3175-3179. https://doi.org/10.21873/anticanres.12581

Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Haque, W, Verma, V, Hatch, S, Suzanne Klimberg, V, Brian Butler, E & Teh, BS 2018, Breast Cancer Research and Treatment, pp. 1-9. https://doi.org/10.1007/s10549-018-4801-3

Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer
Teh, BS, Lewis, GD, Mai, W, Pino, R, Ishiyama, H & Butler, EB 2018, Cancer communications (London, England), vol. 38, no. 1. https://doi.org/10.1186/s40880-018-0281-4

Omission of radiotherapy in elderly women with early stage metaplastic breast cancer
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Breast, vol. 38, pp. 154-159. https://doi.org/10.1016/j.breast.2018.01.005